Table 2.
Assays | Organism Tested | Dose/Concentration | Molecular Targets |
---|---|---|---|
LPS-induced mouse mastitis | Mouse mastitis | 10, 25 and 50 mg/kg | TNF-α ↓, IL-1β ↓, IL-6 ↓, p65 ┴, and IκBα ┴ |
LPS-induced endotozemia and lung injury in mice | Mice (lung) | 25, 50, and 75 mg/kg |
TNF-α ┴, IL-1β ┴, and IL-6 ┴ |
LPS-induced macrophages in mice | Mouse cells | 1–100 μg/mL | IL-6 ↓, MIP-1α
↓, MCP-1 ↓, NF-κB p65 ┴, IκBα ┴, and NO ┴ |
LPS-induced RAW 264.7 cells | Mice (RAW 264.7 cells) | 1, 10, and 100 μM | NO ↓ and TNF-α ↓ |
Inhibitory activity on the histamine release by KU812 cells | KU812 cells | 10 to 30 μmol/L | IL-4 ↓, IL-13 ↓, and (IFN- γ) no effect |
LPS-induced Inflammation in RAW 264.7 cells |
Mice (RAW 264.7 cells) | NO ┴, IL-6 ┴, and PGE2 ┴ | |
Porphyromonasgingivalis-induced human gingival epithelial (HGE) cells |
Human gingival epithelial cells | COX-2 ┴, IL-6 ┴, IL-8 ┴, MMP-1 ┴, MMP-3 ┴, PGE-2 ┴, and IL-4 ┴ |
|
Anti-inflammatory effects on Leptospira interrogans-induced inflammatory response |
Uterine and endometrial epithelial cells of mice |
100 μg/mL | p38 ┴, p-p38 MAPK ↓, ERK ┴, JNK ┴, and p-p65 ↓ |
Protective effects against ovalbumin- (OVA-) induced allergic inflammation |
Mouse model of allergic asthma | 0.5 mg/kg and 1 mg/kg |
SOCS-3 ┴, SOCS-5 ┴, and IFN- γ ↑ |
Alleviation in hepatic fibrosis function |
Diabetic rats and nondiabetic | PAR2 ┴, IL-1β
↓, IL-6 ↓, TNF-α
↓, and TGF-β1 ┴ |
|
Prevention of atopic dermatitis | NC/Nga mice | 1.5 mg/kg | IgE ↓ |
↑ Upregulation; ↓ downregulation; ┴ inhibition.